ANI Pharma (ANIP) reported Q2 EPS of $0.13, $0.06 worse than the analyst estimate of $0.19. Revenue for the quarter came in at $73.9 million versus the consensus estimate of $71.13...
ANI Pharma (ANIP) reported Q1 EPS of ($0.12), $0.31 worse than the analyst estimate of $0.19. Revenue for the quarter came in at $64.5 million versus the consensus estimate of...
We issued an updated report on AMAG Pharmaceuticals (NASDAQ:AMAG) on Mar 6.AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and...
The drug and biotech industry has done relatively well this year, particularly picking up steam in the past three monthsThe chart below shows that the Medical-Biomedical and...
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company that serves patients in need by developing, manufacturing and marketing branded and generic prescription pharmaceuticals, including for diseases with unmet medical needs. The Company is focused on developing and manufacturing niche oncology products (anti-cancer). It has a commercial portfolio of over 101 products with a variety of indications and a portfolio of pipeline products. The Company owns the facility, which includes oral solid dose and liquid manufacturing and packaging, warehouse facilities, analytical, stability, and microbiological laboratory space, and employee office and mechanical space. It also owns a manufacturing facility that includes oral solid dose manufacturing and packaging for pharmaceutical products. Its four pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, one is located in East Windsor, New Jersey and one is located in Oakville, Ontario.